KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Assets Average (2009 - 2026)

Johnson & Johnson recorded quarterly Assets Average of $200.1 billion in Q1 2026, up 2.06% quarter-over-quarter from $196.0 billion in Q4 2025, and up 7.04% year-over-year from $186.9 billion in Q1 2025.

Johnson & Johnson's Assets Average history runs 18 years deep, the most recent figure standing at $200.1 billion for Q1 2026.

  • In Q1 2026, Assets Average rose 7.04% year-over-year to $200.1 billion; the TTM figure through Mar 2026 stood at $200.1 billion (up 7.04% YoY), while the FY2025 annual figure was $189.7 billion, up 9.1% from the prior year.
  • Assets Average came in at $200.1 billion for Q1 2026 at Johnson & Johnson, up from $196.0 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $200.1 billion in Q1 2026 to a low of $166.8 billion in Q4 2023.
  • A 5-year average of $183.5 billion and a median of $180.4 billion in 2022 frame the typical range for Assets Average.
  • Across the five-year window, Assets Average fell 11.43% in 2024 and advanced 10.09% in 2025, its largest moves.
  • Johnson & Johnson's Assets Average stood at $176.4 billion in 2022, then retreated by 5.45% to $166.8 billion in 2023, then increased by 7.43% to $179.2 billion in 2024, then gained by 9.39% to $196.0 billion in 2025, then gained by 2.06% to $200.1 billion in 2026.
  • According to Business Quant data, Assets Average over the past three periods registered $200.1 billion, $196.0 billion, and $193.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 114.53 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 200.05 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 135.21 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 132.78 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 91.55 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 57.65 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 208.08 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 88.26 Bn
10 Gsk 88.34 Bn 83.66 Bn - 314.07 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 200.05 Bn
Dec 28, 2025 196.01 Bn
Sep 28, 2025 193.10 Bn
Jun 29, 2025 193.53 Bn
Mar 30, 2025 186.89 Bn
Dec 29, 2024 179.20 Bn
Sep 29, 2024 179.69 Bn
Jun 30, 2024 176.53 Bn
Mar 31, 2024 169.76 Bn
Dec 31, 2023 166.81 Bn
Oct 1, 2023 178.87 Bn
Jul 2, 2023 193.83 Bn
Apr 2, 2023 191.67 Bn
Jan 1, 2023 181.25 Bn
Oct 2, 2022 176.42 Bn
Jul 3, 2022 178.04 Bn
Apr 3, 2022 180.19 Bn
Jan 2, 2022 180.62 Bn
Oct 3, 2021 177.83 Bn
Jul 4, 2021 174.50 Bn
Apr 4, 2021 173.73 Bn
Jan 3, 2021 172.79 Bn
Sep 27, 2020 164.54 Bn
Jun 28, 2020 156.70 Bn
Mar 29, 2020 156.37 Bn
Dec 29, 2019 156.62 Bn
Sep 29, 2019 155.32 Bn
Jun 30, 2019 152.57 Bn
Mar 31, 2019 151.49 Bn
Dec 30, 2018 154.33 Bn
Sep 30, 2018 155.53 Bn
Jul 1, 2018 156.00 Bn
Apr 1, 2018 156.96 Bn
Dec 31, 2017 156.48 Bn
Oct 1, 2017 154.23 Bn
Jul 2, 2017 148.86 Bn
Apr 2, 2017 143.06 Bn
Jan 1, 2017 140.79 Bn
Oct 2, 2016 140.09 Bn
Jul 3, 2016 138.02 Bn
Apr 3, 2016 134.82 Bn
Jan 3, 2016 133.34 Bn
Sep 27, 2015 132.65 Bn
Jun 28, 2015 130.31 Bn
Mar 29, 2015 129.47 Bn
Dec 28, 2014 131.23 Bn
Sep 28, 2014 133.65 Bn
Jun 29, 2014 134.27 Bn
Mar 30, 2014 133.01 Bn
Dec 29, 2013 129.81 Bn
Sep 29, 2013 125.63 Bn
Jun 30, 2013 122.93 Bn
Mar 31, 2013 121.44 Bn
Dec 30, 2012 120.15 Bn
Sep 30, 2012 117.35 Bn
Jul 1, 2012 115.97 Bn
Apr 1, 2012 114.92 Bn
Jan 1, 2012 112.73 Bn
Oct 2, 2011 111.97 Bn
Jul 3, 2011 110.13 Bn
Apr 3, 2011 105.53 Bn
Jan 2, 2011 100.58 Bn
Oct 3, 2010 95.27 Bn
Jul 4, 2010 92.87 Bn
Apr 4, 2010 94.06 Bn
Jan 3, 2010 93.12 Bn
Sep 27, 2009 89.50 Bn